<?xml version="1.0" encoding="UTF-8"?>
<p>A Phase I/II trial has been initiated to assess safety and immunogenicity of NVCP VLPs administered by the IN route, followed by a live virus challenge to determine the effectiveness of this approach in preventing or limiting NV infection in humans [
 <xref ref-type="bibr" rid="CR0008103">103</xref>].
</p>
